Redmile Group LLC Trims Stock Holdings in Establishment Labs Holdings Inc. $ESTA

Redmile Group LLC lowered its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 8.2% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 103,464 shares of the company’s stock after selling 9,200 shares during the quarter. Establishment Labs comprises about 0.4% of Redmile Group LLC’s portfolio, making the stock its 27th largest position. Redmile Group LLC owned about 0.35% of Establishment Labs worth $5,875,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Establishment Labs by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock worth $2,335,000 after purchasing an additional 9,557 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Establishment Labs by 1.2% during the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after purchasing an additional 299 shares during the period. WINTON GROUP Ltd purchased a new stake in Establishment Labs in the second quarter valued at approximately $651,000. Nebula Research & Development LLC boosted its position in Establishment Labs by 27.9% in the second quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock valued at $692,000 after buying an additional 3,538 shares during the last quarter. Finally, Sei Investments Co. increased its holdings in Establishment Labs by 13.3% in the 2nd quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock worth $2,068,000 after buying an additional 5,668 shares during the period. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Trading Down 0.2%

Establishment Labs stock opened at $91.90 on Wednesday. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The firm has a market cap of $2.70 billion, a PE ratio of -61.68 and a beta of 1.06. The stock’s 50 day simple moving average is $83.63 and its two-hundred day simple moving average is $73.08. Establishment Labs Holdings Inc. has a 12 month low of $33.35 and a 12 month high of $96.99.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The business’s revenue for the quarter was up 44.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.70) earnings per share. Analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Insider Activity

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the sale, the director directly owned 927,504 shares in the company, valued at $69,952,351.68. This trade represents a 10.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 180,000 shares of company stock worth $13,225,275. Corporate insiders own 9.99% of the company’s stock.

Analysts Set New Price Targets

ESTA has been the subject of a number of recent research reports. Mizuho raised their price target on shares of Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. TD Cowen reiterated a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. BTIG Research reissued a “buy” rating on shares of Establishment Labs in a report on Monday, July 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Finally, Citigroup increased their price target on Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $90.43.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.